← Research library

Thymopentin reduced tumor volume in immunocompetent mouse models

Animal research · 2025

What was studied
Hepa1-6 liver tumor comparison used 11 mice per arm pooled from two experiments. The melanoma pretreatment comparison and athymic LM3 comparison used five mice per arm.
Main finding
Hepa1-6 tumor volume at day 24 · 341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.

Reported findings and study design

Reported findings

Thymopentin 20 mg/kg subcutaneously daily versus saline. Hepa1-6 treatment began on day 6 after inoculation and continued through day 24. Melanoma pretreatment began two weeks before inoculation and continued two weeks afterward. The athymic LM3 comparison also included sorafenib 30 mg/kg daily.

Population or model Hepa1-6 liver tumor comparison used 11 mice per arm pooled from two experiments. The melanoma pretreatment comparison and athymic LM3 comparison used five mice per arm.

Dose, route and schedule

Thymopentin 20 mg/kg subcutaneously daily versus saline. Hepa1-6 treatment began on day 6 after inoculation and continued through day 24. Melanoma pretreatment began two weeks before inoculation and continued two weeks afterward. The athymic LM3 comparison also included sorafenib 30 mg/kg daily.

Protocol source ↗ · Original full text, figures and reported group means.

Results · Original full text, figures and reported group means.
MeasureResultComparison, timing and statistics
Hepa1-6 tumor volume at day 24341.10 ± 61.97 mm³ with thymopentin versus 666.01 ± 88.62 mm³ with saline (mean ± SEM, p<0.001). The treated mean was 48.8% lower.
B16-F10 melanoma tumor volume at day 14461.36 ± 93.85 mm³ versus 1,155.11 ± 232.42 mm³ (mean ± SEM, p<0.01) in the pretreatment model.
Athymic LM3 model and cell assaysThymopentin failed to suppress tumor growth in the athymic model, and direct treatment did not reduce Hepa1-6 cell viability in vitro. Sorafenib inhibited growth in the athymic comparison.
Adoptive T-cell transfer in melanoma-bearing mice170.54 ± 30.81 mm³ with thymopentin plus OT-1 cells versus 368.64 ± 130.24 mm³ with OT-1 cells alone (p<0.05, five mice per group).
Immune readoutsThe authors reported increased thymus mass and thymic T-cell counts and fewer PD-1/TIM-3 double-positive T cells in the tumor model.

The liver tumor comparisons used different cell lines in immunocompetent and athymic mice. The results support an immune mechanism in the tested models and leave clinical efficacy and durability unresolved. The melanoma experiment started before tumor implantation.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The liver tumor comparisons used different cell lines in immunocompetent and athymic mice. The results support an immune mechanism in the tested models and leave clinical efficacy and durability unresolved. The melanoma experiment started before tumor implantation.

Source details

Original journal article

Original full text, figures and reported group means.

Sources checked

Added to the library

Citation

Animal / experimentalFull text available

M. A. Hossain, Y. Zhang, L. Ji, Y. Chen, Y. Luan, Y. Si, Y. Fang, J. Qiu, Z. Wang, G. Liu. Thymopentin reduced tumor volume in immunocompetent mouse models Biomedicines 13(10), 2494.

Study source ↗ · DOI 10.3390/biomedicines13102494 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards